ATIM-37 - Phase II, open-label, single arm, multicenter study of avelumab with hypofractionated radiation (HFRT) for adult patients with secondarily transformed IDH-mutant glioblastoma (GBM)

Saturday, November 23

5:00 PM - 7:00 PM

Location: Ballroom Lawn

Poster Presenting Author(s)

JS

Johsua S. Silverman

NYU Langone Health
TH

Tsivia Hochman

NYU Langone Health
LN

Lakshmi Nayak

Dana-Farber Cancer Institute
IA

Isabel Arrillaga-Romany

Attending Neuro-Oncologist
Massachusetts General Hospital
Eudocia Lee

Neuro-Oncology
Dana-Farber Cancer Institute
AP

Amie Patel

New York University Langone Health
MD

Malcolm Delara

NYU Langone Health
FH

Fraustina Hsu

NYU Langone Health
TI

Tooba Imtiaz

NYU Langone Health
LM

Lori Magnelli

EMD Serono
Jennie Taylor

Assistant Professor
Division of Neuro-Oncology UCSF
Timothy Cloughesy

Professor
University of California Los Angeles
Erik Sulman

Professor and Vice Chair of Research, Department of Radiation Oncology and Co-director of the Brain and Spine Tumor Center in the Laura and Isaac Perlmutter Cancer Center
NYU Langone School of Medicine
JG

John Golfinos

New York University Langone Medical Center
DZ

David Zagzag

New York University Langone Health
Matija Snuderl

New York University Langone Health
JG

Judith D. Goldberg

NYU Langone Health
Andrew Chi

Senior Director
Neon Therapeutics